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Summary Background: In patients with chronic respiratory failure (CRF) nocturnal
mechanical ventilation (NMV) confers increased exercise tolerance. The hypothesis
tested in the present study was that the increased exercise performance is associated
with increased quadriceps strength. Methods: In 28 patients with CRF due to chronic
obstructive pulmonary disease and restrictive thoracic disease (post-tuberculosis-
sequelae, scoliosis and obesity-hypoventilation) NMV was started. Before and after 2-
month NMV the exercise tests, namely shuttle and 6-min walking distance, were
performed. Furthermore, quadriceps strength was measured as the twitch tension
elicited by magnetic stimulation the femoral nerve (TwQ) and the maximum voluntary
contraction force (MVC). Results: After 2 months therapy with NMV there was
significant clinical and blood gas improvement. NMV significantly improved the
walking distance by approximately 18% but there was no improvement in TwQ or MVC,
the data could exclude a 15% improvement in TwQ with 82% confidence. Conclusion:
The strength of quadriceps does not change after 2 months of effective NMV in
patients with CRF despite a marked increase in endurance time. Factors other than
quadriceps strength account for the improved performance.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
In patients with chronic lung disease exertional
dyspnoea is a common complaint and reduced daily
activity is often a primary concern. Using a move-
ment detector (pedometer) as a global test of daily
activity we have previously reported a relationship
between the severity of chronic respiratory failure
(CRF), in terms of hypercapnia, and daily activity.1
Moreover, we extended this observation to show
that both exercise endurance2 and daily activity,
judged by pedometer count,1 increased after 3
months of nocturnal mechanical ventilation (NMV)
in patients with CRF.
Although NMV relieves symptoms of hypoventila-
tion and improves blood gases in patients with CRF,
little is known about the precise mechanism
responsible for this increased exercise tolerance.
Whilst we acknowledge that the underlying patho-
physiology of the impaired physical activity is
multifactorial, one contribution could arise from
pre-existing dysfunction of the quadriceps in
patients with untreated CRF, which may be resolved
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by NMV therapy. This rationale is based on the study
of patients with chronic obstructive pulmonary
disease (COPD) who are recognised to have reduced
quadriceps strength3 as well as a reduced oxidative
capacity.4
The aim of this study was to investigate whether
quadriceps strength changes in patients with
improved exercise performance after long-term
NMV. We hypothesised that the strength of the
main muscle of the lower extremities would
increase proportionately to the development of
the walking distance. Because treatment of CRF
could improve cognitive function (and therefore
affect performance on volitional tests of quadri-
ceps function) we used both volitional and non-
volitional tests of quadriceps function.
Methods
Patients
To be eligible for the study, subjects were required
to be hypercapnic and clinically stable (no hospital
admission for at least 1 month prior to the study
and no significant change in blood gases 1 month
before admission). Subjects were not considered if
they had rapidly progressive neuromuscular dis-
eases (e.g. amyotrophic lateral sclerosis), severe
acidosis (defined as pHo7:30) or orthopaedic
walking disability. The protocol was approved by
our ethical review committee and all subjects gave
written informed consent to participate.
Measurements
Baseline measurements were performed prior to a
run-in period of NMV. Spirometry was done with a
Masterlab (J .ager, W .urzburg, Germany). Resting
daytime capillary blood gases, from a hyperaemic
earlobe (rubefacient; Finalgons Thomae, Boehrin-
ger Ingelheim, Germany), were measured with a
Gas Check (AVL, Bad Homburg, Germany) while
breathing room air. The maximal inspiratory (Pimax)
and expiratory pressures (Pemax) were taken as the
highest single value of five measurements, using
the technique of Black and Hyatt.5
Quadriceps strength
Quadriceps strength of the right leg was measured
using an apparatus similar in principle to that
described by Edwards and co-workers,6 but mod-
ified to permit magnetic stimulation of the femoral
nerve.7,8 The ankle was connected to a strain gauge
with integrated transducer (KM1100-S, Megatron
Elektronik, M .unchen, Germany) by an inextensible
ankle strap. The signal was then passed via a carrier
amplifier (constructed by technician M. Klauke) and
a 12-bit analogue–digital board (Lab-PC+, National
Instruments, M .unchen, Germany) to a PC running
Labview software (Labview 5.0, National Instru-
ments, M .unchen, Germany) sampling at 2 kHz.
To minimise twitch potentiation, quadriceps,
twitch tension (TwQ) was measured first using the
method of Polkey et al.7 after a 20min period of
relaxation. Femoral nerve stimulation was per-
formed using a 45mm figure-of-eight coil powered
by a Magstim 200 stimulator (The Magstim Co,
Whitland, Dyfed, Wales). Stimulations were per-
formed at 50%, 80%, 90% and 100% of stimulator
output to assess supramaximality. Stimulations
were given in pseudorandom order and 5 stimuli
were obtained at each level. We defined supramax-
imality as a change in TwQ of 0.5 kN or less in
moving from 90% to 100% of maximal stimulator
output.
The patients were then asked to make three
maximum voluntary contraction (MVC) manoeuvres
while lying supine; the largest of these was
selected for analysis. The handgrip strength of
the right hand was measured using a handgrip
dynamometer (baseline hydraulic hand dynam-
ometer, Fabrication Enterprises Inc., New York,
USA); again the best of three maximum voluntary
efforts was recorded.
Shuttle walking test
The shuttle-walk test was performed following a
standard protocol.9 Perceived breathlessness,
rated using a visual analogue scale from 0 (not
short of breath) to 10 (extremely short of breath),
was measured before and immediately after walk-
ing distances. Perceived leg exertion was also
scored, using a similar visual analogue scale, before
and immediately after each test. Before starting
and at the end of the walking test oxygen
saturation was measured (Minolta–Pulsox-31, ASVL
Medical Instruments, Schaffhausen, Swiss).
Six-min walking distance (6-min WD)
The 6-min WD was performed according to the
established protocol.10 Measurements of perceived
breathlessness, leg exertion and oxygen saturation
are described above.
Study protocol
Baseline blood, lung function and ventilatory
variables were measured at rest, prior to starting
the study. Subsequently, each walking test was
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performed twice in randomised order, on consecu-
tive days with at least a 2 h rest period between
each test, allowing the subjects to get familiarised
with the different tests. Once the preliminary
familiarisation was complete, the baseline walking
tests were then performed on the following day in
random order (8 a.m. or 4 p.m.), respectively.
Assessment of quadriceps strength was performed
on this day also. After completion of the baseline
tests, patients were offered NMV. All patients had a
5-day run-in period of NMV to determine the
optimal ventilator settings. Both pressure- and
volume-targeted ventilators were used. Details
documenting our practice for initiation of NMV
have been described elsewhere.11
None of the 28 included patients participated in
an exercise rehabilitation program during the study
period. Two months later all measurements were
repeated.
Statistics and conventions
For TwQ data are given as the mean of all stimuli
given (usually five) for each experimental condi-
tion. Volitional tests (MVC and handgrip strength)
are reported as the greatest single value obtained.
Results are expressed as mean7standard devia-
tion (SD). The significance for matched pairs was
determined by the t-test for dependent samples in
case of Gaussian distribution, otherwise Wilcoxon
test was used. Correlations were tested with
Pearson product–moment correlation. In all cases,
a two-sided P value of o0:05 was taken as
significant. Statistical analysis was performed with
the PC-program STATISTICA,12 except power analy-
sis, which was done with Gpower.13
Results
Anthropometric data for all the participating
patients are presented in Table 1. At baseline all
patients had CRF, with daytime hypoxaemia and
hypercapnia (Table 2). NMV resulted in a significant
clinical improvement as well as improvement in
daytime blood gases; mean PaCO2 fell from 6.83 to
5.95 kPa (Po0:0001) and mean PaO2 rose from 6.82
to 7.88 kPa (Po0:0008).
Twenty-four patients used pressure-targeted
ventilators in timed mode (inspiratory pressure:
18.872.5 cm H2O, expiratory pressure: 5.571.5 cm
H2O, breathing frequency: 18.073.3/min and
inspiratory time: 39.976.6% of the cycle). Four
patients used volume-targeted ventilators also in
timed mode. The patients compliance with NMV
was confirmed by examination of the hours of use
recorded by their machines which was a median of
6.4 h per patient per night.
Muscle strength data
The pooled baseline data relating stimulator output
to TwQ are shown in Fig. 1. Further data, which are
reported in the results section of this paper, refer
to the mean TwQ elicited by stimuli given at 100% of
stimulator output.
Compared to normal values obtained in subjects
of a similar age8 (TwQ 9.4 and MVC 37.2)
our strength values were reduced in the patients
(Table 3) at baseline; NMV did not improve TwQ or
MVC. A power calculation was done on the data
after 28 patients were evaluated. This calculation
showed an 82% chance of detecting a 15% change in
the treatment group (1 kN) in TwQ if the data were
treated as two tailed; alternatively if the data are
treated as one tailed the data exclude a 15%
increase with 90% confidence. Similarly, we found
no difference between both subgroups with CRF
(i.e. COPD and restrictive thoracic disease) regard-
ing amount of change in TwQ (P ¼ 0:23). We can
exclude an effect of NMV on MVC of 15% improve-
ment (2.9 kN) on a power level of 0.85 (one tailed).
The data for handgrip strength were similar; an
effect of NMV on maximal handgrip strength of 10%
improvement (3.3 kN) on a power level of 0.98 (one
tailed) was excluded. We found no significant
change in Pemax (P ¼ 0:16), but an improvement in
Pimax of about 15% (P ¼ 0:013; Table 2).
Walking performance
Compared to normal values reported in the litera-
ture10 the 6-min WD was reduced (approximately
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Table 1 Characterisation (anthropometric data
and diagnosis) of the patients.
Parameter Mean7SD
Age (years) 59.5710.9
BMI (kg/m2) 24.575.9
Sex (n/%)
Male 13/46.4
Female 15/53.6
Diagnosis (n/%)
COPD 20/71.4
Scoliosis 4/14.3
Post-TBC 2/7.1
Neuromuscular 1/3.6
OHS 1/3.6
Abbreviations: post-TBC: post-tuberculosis sequelae;
OHS: obesity hypoventilation syndrome.
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60% predicted). As shown in Table 4, NMV signifi-
cantly improved the walking distance as judged by
both the 6-min WD and the shuttle walk; the
magnitude of improvement was approximately 18%
whether judged by the 6-min WD or the shuttle
walking. Perceived breathlessness and leg exertion
was unchanged both before and immediately after
exercise, but it must be recalled that the post-
exercise values were obtained after a significant
greater walking distance than their baseline values.
Finally, no correlations were found between the
improvement in walking distance and the changes
in PaO2, PaCO2 and Pimax (P > 0:05).
Discussion
Our data show that 2 months of NMV therapy in
patients with CRF does not increase quadriceps
strength despite an increase in walking distance.
Thus, it seems implausible that changes in muscle
strength could account for improved performance.
Before discussing these findings further, the main
methodological issues will be addressed.
Critique of the method
Study design
On initial review our study hypothesis seems
implausible and therefore it could be argued that
our results are unsurprising. In fact, however, there
are good data to suggest that blood gas abnormal-
ities can alter tension generation,14 and arterial
blood gas tensions changed in our patients after
administration of NIV. Therefore, we believe that
our hypothesis, that NMV is associated with
increased quadriceps strength, was reasonable.
Ideally, we should have investigated the effects
of NMV on muscle strength using a prospective
randomised control design. Indeed, there is a need
for further randomised controlled trials in patients
with CRF due to COPD to assess the value of the
treatment. However, the sample size required for
an RCT (Randomised Controlled Trials) to assess the
value of chronic NIV in COPD is too large for a single
institution; and this was therefore not an option for
this study. We did collect parallel data from
patients who failed to tolerate NMV but we have
not presented this because this ‘control’ group was
not randomly generated.
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Table 2 Blood gases, lung function and maximal inspiratory and expiratory muscle strength of the patients at
baseline, after an observation period of 2 months.
Parameter Baseline After 2 months Delta baseline (after 2 months) P
PO2 (kPa) 6.8271.03 7.8871.01 1.1071.48 0.0008
PCO2 (kPa) 6.8370.71 5.9570.60 0.8770.95 0.0001
pH 7.3770.03 7.3970.04 0.0170.05 0.24
BE 4.272.5 2.973.0 1.073.9 0.28
HCO3 (mmol/l) 30.073.2 27.673.1 2.074.2 0.06
VC (l) 1.7670.61 1.8370.75 0.0270.47 0.83
VC (%pred) 51.6710.9 52.3715.0 0.9711.9 0.72
FEV1 (l) 0.8870.37 0.9370.40 0.0470.17 0.21
FEV1 (%VC) 45.7712.6 52.4720.1 5.9718.9 0.23
Pimax 44.0713.4 50.4717.3 6.8713.3 0.0132
Pemax 91.6733.9 96.5736.1 6.3722.7 0.16
Abbreviations: VC: vital capacity; FEV1: forced expiratory volume in 1 s; Pimax: maximal inspiratory pressure; Pemax: maximal
expiratory pressure.
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Fig. 1 Pooled baseline data relating stimulator output to
TwQ performed at 50%, 80%, 90% and 100% of stimulator
output.
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Was the ventilation effective?
Highly significant improvements in blood gas ten-
sions were observed in the NMV group who also
reported symptomatic improvement and demon-
strated a high rate of ventilator use. Thus we
believe NMV was given effectively, and compliance
was also confirmed.
Did exercise performance really improve?
Our hypothesis requires a genuine increase in
exercise performance as a result of NMV. Patients
undertaking other possible confounding interven-
tions (such as exercise training programs) were
excluded from this study; therefore it is reasonable
to assume that the improvements seen in this study
are due to NMV. We doubt that improvement can be
attributed to a ‘learning effect’ since the shuttle
walking test has high reproducibility.9 The average
level of improvement in walking distances was 18%,
which is comparable to changes of walking distance
after other kinds of treatments, for instance,
rehabilitation15 or lung volume reduction surgery.16
Sample size
Because the data are negative we considered it
especially important to avoid reporting a ‘false
ARTICLE IN PRESS
Table 3 Quadriceps twitch tension (TwQ) performed at 50%, 80%, 90% and 100% of stimulator output, maximum
voluntary contraction of quadriceps and maximum handgrip in patients with NMV and controls at baseline, after
an observation period of 2 months.
Parameter Baseline After 2 months Delta baseline (after 2 months) P
Quadriceps 50% (kN) 3.972.7 3.972.0 0.171.7 0.87
Quadriceps 80% (kN) 5.973.5 5.372.8 0.671.8 0.07
Quadriceps 90% (kN) 6.473.4 5.972.9 0.671.9 0.12
Quadriceps 100% (kN) 6.673.4 6.172.9 0.571.8 0.12
Quadriceps maximum (kN) 19.477.7 21.278.8 1.875.6 0.09
Handgrip maximum (kN) 33.0710.4 33.3710.2 0.774.4 0.45
Table 4 Details concerning distances, dyspnoea, leg exertion and SaO2 before and after shuttle walking and 6-
min walking in the patients at baseline, after an observation period of 2 months.
Parameter Baseline After 2 months Delta baseline (after 2 months) P
Shuttle walking
Distance (m) 193.97118.5 234.87124.7 34.8776.5 0.0500
Dyspnoea before (VAS 0-10) 1.571.8 0.871.1 0.771.5 0.07
Dyspnoea after (VAS 0–10) 4.871.7 4.370.9 0.471.8 0.31
Dyspnoea delta (VAS 0–10) 3.371.0 3.571.2 0.371.5 0.51
Leg exertion before (VAS 0–10) 0.671.1 0.671.1 0.171.3 0.89
Leg exertion after (VAS 0–10) 2.471.9 2.671.9 0.272.1 0.69
Leg exertion delta (VAS 0–10) 1.871.2 2.171.5 0.371.5 0.48
SaO2 before (%) 89.974.1 90.272.5 0.274.1 0.89
SaO2 after (%) 79.177.3 78.878.3 0.275.2 0.91
SaO2 delta (%) 10.875.9 11.477.5 0.476.3 0.85
6-min walking
Distance (m) 307.37142.3 350.27153.8 54.47102.3 0.0104
Distance (%pred) 57.0726.6 64.5729.2 9.6719.5 0.0172
Dyspnoea before (VAS 0–10) 1.671.5 1.471.6 0.371.5 0.65
Dyspnoea after (VAS 0–10) 4.871.4 5.071.0 0.2 7 1.4 0.59
Dyspnoea delta (VAS 0–10) 3.271.3 3.671.4 0.471.5 0.21
Leg exertion before (VAS 0–10) 1.471.3 1.071.4 0.470.8 0.09
Leg exertion after (VAS 0–10) 3.371.8 2.972.0 0.472.0 0.48
Leg exertion delta (VAS 0–10) 1.971.3 1.971.8 0.171.6 0.96
SaO2 before (%) 87.679.1 89.774.3 2.178.2 0.32
SaO2 after (%) 81.2710.2 79.5710.6 1.775.5 0.24
SaO2 delta (%) 6.475.9 10.278.1 3.877.0 0.0465
Abbreviations: VAS: visual analogue scale.
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negative’ result and performed an interim sample
size calculation showing a need to extend the
study. The final data show an 18% improvement in
exercise performance but exclude a 15% increase in
TwQ with an 82% (two-tailed) or 90% (one-tailed)
confidence. This level of confidence is consistent
with levels of confidence employed in trials of
novel therapeutic agents. It is not possible to
exclude an improvement for every subgroup with
adequate power. The calculated power is only valid
for the complete cohort; an exclusion of positive
results for every possible subgroup, e.g. for
patients with restrictive disease (n ¼ 8), would
require a considerably larger sample size.
Kind of peripheral muscle test
We took the quadriceps strength as a surrogate for
muscle function of the lower extremities. However,
based on our results, another hypothesis would be
that the improved walking distance might result
from increased endurance rather than muscle
strength; this hypothesis was not tested in the
present study.
Significance of the findings
There is widespread agreement that for certain
diagnostic groups (notably neuromuscular17) NMV
can palliate symptoms of nocturnal hypoventilation
and improve longevity. However, in patients whose
CRF is due to respiratory disease diminished
exercise performance also contributes to symp-
toms. The present data are consistent with a recent
study from our group which showed the beneficial
effects of NMV on three different exercise tests
(i.e. inspiratory threshold loading, ergometry test,
shuttle walk) in patients with CRF.2 Furthermore,
we demonstrated a significant improvement in
daily activity levels following NMV in patients with
CRF, using a pedometer over a 1-week period in the
patients’ natural surroundings at home.1 Although
improved quadriceps muscle strength may be
associated with increased activity the present data
do not show this within a 2-month time frame.
It is of interest to speculate by which mechan-
isms NMV improves exercise performance. Deter-
minants of exercise capacity in CRF are
multifactorial; indeed a number of mechanisms
operate simply in relation to the locomotor muscles
and their cortical control. For example, when
patients with COPD exercise, quadriceps fatigue is
a frequent finding18 and our data do not exclude a
switch in fibre type which could improve endur-
ance. We do, however, think this is unlikely because
therapies which change fibre type19 also result in
increased strength.20
Improvements in the capacity of the respiratory
muscles may also account, at least in part, for the
improvements in the endurance performance.
Thus, due to true change in the contractile
properties of the muscle, the improvement in
Pimax with NMV (from 44.0 to 50.4 cm H2O) could,
at least in part, explain the improvement in
endurance. This hypothesis would require confir-
mation using phrenic nerve stimulation, which was
not performed in the present study. Improvement
in Pimax without a corresponding improvement in
the twitch transdiaphragmatic pressure elicited by
phrenic nerve stimulation would suggest an im-
provement in the subjects ability to perform the
tests rather than a true change in contractile
properties.
Another postulated mechanism to explain how
NMV works may be an increase of lung compli-
ance.21 However, although compliance was not
measured in the current study, no change in VC or
airway resistance was observed in the NMV group
making this explanation less plausible. Finally,
haemodynamic adaptations may also contribute to
the improved endurance. For example, we have
recently found a marked reduction in pulmonary
hypertension at rest and during exercise after 1
year of NMV.22
We conclude that the strength of quadriceps did
not change after 2 months of NMV in patients with
CRF despite a marked increase in endurance time.
Factors other than quadriceps strength account for
the improved performance at this time point.
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